CurrentmhnPolicy CP.PMN.137

Clinical Policy: Carbamazepine ER (Equetro)

Policy governing medical necessity and prior authorization criteria for extended-release carbamazepine (Equetro) for members covered under Centene-affiliated health plans (Commercial and Medicaid). Affects prescribers and reviewers requesting coverage for Equetro.

Policy Summary

Payermhn

PolicyClinical Policy: Carbamazepine ER (Equetro)

Policy CodePolicy CP.PMN.137

Change TypeNo material changes

Effective Date06.01.18

Next Review Date

Key ActionProvider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3 indicationsFDA approved indications listed

1,600 mg/daymax dose (bipolar/epilepsy)

1,200 mg/daymax dose (trigeminal)

ER capsules 100/200/300 mgproduct availability

Commercial, Medicaidlines of business

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Initial Approval — Bipolar Disorder, Trigeminal Neuralgia, or Epilepsy

Covered when ALL of the following are met:

Initial approval criteria: 1. Diagnosis of one of the following: a. Bipolar disorder; b. Trigeminal neuralgia; c. Epilepsy (partial seizures, generalized tonic-clonic seizures, or mixed types). 2. If diagnosis is bipolar disorder or trigeminal neuralgia, age >= 18 years. 3. Member meets ONE of: a. Request is for a member in a State with limitations on step therapy in certain mental health settings (see Appendix D); b. Member must use immediate‑release carbamazepine unless contraindicated or clinically significant adverse effects are experienced. 4. Member meets ONE of: a. Request is for a member in a State with limitations on step therapy in certain mental health settings (see Appendix D); b. Member must use extended‑release carbamazepine (e.g., Tegretol XR) unless contraindicated or clinically significant adverse effects are experienced. 5. Dose does not exceed: a. Bipolar disorder or epilepsy: 1,600 mg per day; b. Trigeminal neuralgia: 1,200 mg per day.see node text

Logic includes alternative paths for states with step therapy or redirection limitations.

inv-02: Continuation (Renewal) — Bipolar Disorder, Trigeminal Neuralgia, or Epilepsy

Covered for continuation when ALL of the following are met:

Continuation criteria: 1. Member meets ONE of: a. Currently receiving medication via Centene benefit or previously met initial approval criteria; b. Documentation supports member is currently receiving Equetro for bipolar disorder or epilepsy and has received it for at least 30 days. 2. Member is responding positively to therapy. 3. If request is for a dose increase, new dose does not exceed: a. Bipolar disorder or epilepsy: 1,600 mg per day; b. Trigeminal neuralgia: 1,200 mg per day.dose limits as specified

Continuation requires demonstrated benefit and adherence to dose caps.

inv-03: Other Diagnoses/Indications

Requests for uses not covered by the main criteria:

Other uses: 1. If the drug had a label change within the last 6 months that is not yet reflected in this policy, refer to: a. For drugs on the formulary/PDL: no coverage criteria policy (CP.CPA.190 for commercial; CP.PMN.255 for Medicaid); b. For drugs NOT on the formulary/PDL: non‑formulary policy (CP.CPA.190 for commercial; CP.PMN.16 for Medicaid). 2. If the requested use is not listed in section III and criterion 1 does not apply, refer to the off‑label use policy for the relevant line of business (CP.CPA.09 for commercial; CP.PMN.53 for Medicaid).N/A

Refer to formulary/non‑formulary or off‑label policies as specified.

Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies sufficient clinical documentation of efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 (Commercial) or CP.PMN.53 (Medicaid), or other evidence of coverage documents.

Use of carbamazepine extended‑release (Equetro) for absence (petit mal) seizures is not medically necessary / not authorized.

Provider Requirements and Prior Authorization Actions

Prior Authorization

Prior authorization requirements

Prior authorization requires that the request meets the policy's initial or continuation criteria, including diagnosis, age (if bipolar disorder or trigeminal neuralgia), dose limits, and other required elements. Provider must submit supporting clinical documentation (such as office chart notes, lab results, or other clinical information) demonstrating the member meets all approval criteria.

Applies to initial and continuation requests
Dose limits: bipolar disorder/epilepsy ≤ 1,600 mg/day; trigeminal neuralgia ≤ 1,200 mg/day

Step Therapy

Step therapy / redirection

Member must use immediate‑release carbamazepine prior to Equetro unless contraindicated or clinically significant adverse effects are experienced. Extended‑release carbamazepine (e.g., Tegretol XR) must also be tried unless contraindicated or clinically significant adverse effects are experienced, except where state-specific redirection limits apply (see Appendix D).

Step therapy may be prohibited or limited in certain states — refer to Appendix D for state-specific rules

Documentation Required

Supporting clinical documentation required

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria. Documentation should show diagnosis, age (when applicable), prior therapies tried and reason for failure or intolerance, current dosing, treatment response for continuation requests, and any relevant safety testing or genetic results (e.g., HLA-B*1502 when indicated).

Include evidence of trial and failure or contraindication to immediate‑release carbamazepine (and extended‑release when required) unless exemption applies
For continuation requests, document at least 30 days of current Equetro use or prior authorization history as specified

Denial Risk

Documentation insufficiency / non‑covered indication

Requests missing documentation that the member meets all approval criteria will be considered insufficient and may be denied. Requests for non‑FDA approved indications not addressed in this policy are not covered unless sufficient documentation of efficacy and safety is provided per off‑label use policies (CP.CPA.09 for commercial; CP.PMN.53 for Medicaid) or there is an evidence of coverage document permitting the use.

Non‑FDA indications require supporting evidence per off‑label policies CP.CPA.09 (commercial) or CP.PMN.53 (Medicaid)
Absence seizures (petit mal) are not covered under this policy

Definitions and Risks

Absence seizures (petit mal) — definition and clinical note

DefinitionAbsence (petit mal) seizures are a seizure type for which carbamazepine (Equetro) is not indicated and may experience increased frequency of generalized convulsions with carbamazepine use.

Clinical implicationCarbamazepine should not be used to treat absence seizures due to risk of worsening generalized convulsions.

Related FDA statementEquetro is not indicated for the treatment of absence seizures (petit mal).

Seizure types covered by Equetro (contrast)Equetro is indicated for partial seizures with complex symptomatology, generalized tonic‑clonic seizures, and mixed seizure patterns—but explicitly excludes absence seizures.

HLA-B*1502 risk — boxed warning and clinical relevance

DefinitionHLA‑B*1502 is a genetic allele associated with an increased risk of serious dermatologic reactions to carbamazepine, and is referenced in the product boxed warning.

Regulatory warningBoxed warning for Equetro includes serious dermatologic reactions and HLA‑B*1502 allele.

Clinical actionConsider genetic risk (HLA‑B*1502) when evaluating patients for carbamazepine therapy due to potential for severe skin reactions.

Related contraindications/alertsBoxed warnings for Equetro also include aplastic anemia and agranulocytosis; review full contraindication list before prescribing.

OpenPayer

Clinical Policy: Carbamazepine ER (Equetro)

Coverage Criteria for Carbamazepine ER (Equetro)

Provider Requirements and Prior Authorization Actions

Background

Definitions and Risks